Podcast Summary: Bloomberg Businessweek – "The Next Biotech Breakthrough"

Date: February 5, 2026
Hosts: Carol Massar & Tim Stenovec
Guest: Jenny Rook, Founder and Managing Director, Genoa Ventures

Episode Overview

In this episode, hosts Carol Massar and Tim Stenovec discuss the rapidly evolving intersection of artificial intelligence (AI) and biotechnology, especially as it relates to research, investment, and drug development. The show features a segment with Jenny Rook, a leading biotech investor, offering insights from the JP Morgan Healthcare Conference and her perspective on biotech trends, funding, and the impact of AI on the field.

Key Discussion Points & Insights

1. OpenAI’s Introduction of Prism for Scientific Research

• [00:14] Tim Stenovec breaks the news of OpenAI’s new tool, Prism, aimed at supporting scientists in academic writing, collaboration, and research paper drafting using the GPT-5.2 model.

  • “OpenAI is releasing a free tool. It’s aimed at making it easier for scientists to use ChatGPT to draft research papers and collaborate with colleagues as part of a larger effort to position its chatbot as an aid for scientific work and discoveries.” (Tim Stenovec, 00:14)

• Features of Prism:

  • Cites papers (with caveats about generating non-existent citations)
  • Can turn handwritten diagrams into computer images

• [00:51] Carol Massar and Jenny Rook quickly warn about issues of plagiarism and false citations.

  • “Just be careful not to copy somebody else’s work!” (Carol Massar, 00:51)

2. The JP Morgan Healthcare Conference: Industry Pulse

• [02:10] Jenny Rook shares her takeaways from the 2026 JP Morgan Healthcare Conference in San Francisco.
  • The mood was “cautiously optimistic,” a sentiment echoed from the previous year, but with more energy and participation this time.
    • “The headline that I kept hearing...was cautiously optimistic. Which, you know, I’ll take it after the last couple of years...there was a palpably different feel. There were more people actually this year than last year.” (Jenny Rook, 02:10)
  • High attendance and engagement, signaling “a lot of energy around the very real impacts...of AI on health and science and also some of the shifts in the availability of funding.”

3. Opportunities & Funding in Early-Stage Biotech

• [03:22-04:04] Hosts inquire about the state of early-stage innovation and funding, referencing the traditional reliance on university/federal funding and new challenges ahead.

  • Tim asks, “Are you also seeing like the early stage stuff? ... Are the opportunities still there?...Are you having a hard time picking and choosing which investments to make?” (Tim Stenovec, 03:22)

• Jenny Rook’s Response:

  • Opportunities persist due to the ongoing need to uncover new science.
  • AI is speeding the pace at which data is turned into actionable research and business plans — creating a "flywheel" effect.
    • “That flywheel is spinning faster with the assistance of AI and other kinds of connectivity and collaboration.” (Jenny Rook, 04:04)
  • Funding shortfalls from traditional sources are driving researchers to consider commercial paths, often resulting in new opportunities for early-stage investors.
    • “We're seeing...perhaps counterintuitively, this is creating a new category or more opportunities for the early stage investor where perhaps a researcher who hadn't been thinking of commercializing their research is starting to think, ‘Well, is there an opportunity to bring this out in a way where I can access both commercial dollars and...funding for advancing science?’” (Jenny Rook, 04:04)

4. The Realistic Timelines of AI in Biotech

• [05:45] Carol asks whether AI has dramatically reduced the time frames for biotech discovery and product development.

  • “Does the time frame for figuring out developments in this area— is it sped up because of AI or is it still going to take a while?” (Carol Massar, 05:45)

• Jenny Rook’s Insights:

  • AI’s accelerative impact is largely at the beginning of the process — such as discovering and designing new drugs or diagnostics.
  • The downstream development, regulatory, and commercialization processes remain lengthy and expensive.
    • “Perhaps it [AI] can help us come up with novel medicines or novel targets... But we’re still looking at...the multi-year, many hundreds of millions of dollars journey to bring a drug properly through clinical development.” (Jenny Rook, 06:14)
  • Urges listeners to “temper our excitement” with the realities of those timelines.

5. Overall Sentiment and Memorable Quotes

• Cautiously optimistic outlook for biotech and healthcare investment in 2026.
• AI perceived as a rising tide, speeding early research and presenting new models for innovation and investment.
• The sector is adapting to changes in traditional funding, creating new opportunities for entrepreneurs and early-stage investors.
• “We have to keep in mind that many of the accelerations that we're talking about that AI can bring...is still happening at the beginning of a journey.” (Jenny Rook, 06:14)

Notable Quotes by Timestamp

• [00:14] Tim Stenovec:
  “OpenAI is releasing a free tool. It’s aimed at making it easier for scientists to use ChatGPT to draft research papers and collaborate with colleagues as part of a larger effort to position its chatbot as an aid for scientific work and discoveries.”

• [00:51] Carol Massar:
  “Just be careful not to copy somebody else’s work!”

• [02:10] Jenny Rook:
  “The headline that I kept hearing...was cautiously optimistic. Which, you know, I’ll take it after the last couple of years...there was a palpably different feel.”

• [04:04] Jenny Rook:
  “That flywheel is spinning faster with the assistance of AI and other kinds of connectivity and collaboration.”

• [06:14] Jenny Rook:
  “...perhaps it can help us come up with novel medicines or novel targets for medicines. But we’re still looking at the beginning of the multi-year, many hundreds of millions of dollars journey to bring a drug properly through clinical development.”

Timestamps for Important Segments

• 00:14 | OpenAI’s Prism for scientists
• 02:10 | Biotech industry mood from JP Morgan Healthcare Conference
• 04:04 | Changing funding landscape and opportunities for early-stage investors
• 05:45 | Impact of AI on development timelines in biotech

Tone and Conclusion

The discussion is optimistic yet balanced, highlighting both the transformative promise of AI in biotech and the persistent realities of industry timelines and funding challenges. Jenny Rook’s perspective roots the conversation in the driven, adaptable nature of scientific entrepreneurs, and the evolving dynamic of funding in a post-pandemic landscape.

Final Thought:
The next biotech breakthrough will ride the ongoing convergence of technology and biology, with AI accelerating early discovery but not sidestepping the necessity of patience and rigor in translating research to real-world medicines.